More tools:Markets·Screener·Research·Chat

Adaptive Biotechnologies Corporation Common Stock (ADPT) Financial Statements

Adaptive Biotechnologies Corporation Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001V0GG18
XNAS · usd
24.34▲ 0.06 (0.25%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close24.28
Day's Range23.62 – 24.60
52-Week Range12.00 – 26.87
Volume1.4M
Avg Volume2.1M
Share Statistics
Shares Outstanding
Employees624
ExchangeXNAS
Listed2019-06-27
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Adaptive Biotechnologies Corporation Common Stock (ADPT)
What is Adaptive Biotechnologies Corporation Common Stock's Market Cap?
Adaptive Biotechnologies Corporation Common Stock's Market Cap is $3.9B, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's Enterprise Value?
Adaptive Biotechnologies Corporation Common Stock's Enterprise Value is $3.7B, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's Price / Sales?
Adaptive Biotechnologies Corporation Common Stock's Price / Sales is 12.6×, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's EV / Revenue?
Adaptive Biotechnologies Corporation Common Stock's EV / Revenue is 12.1×, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's EV / EBITDA?
Adaptive Biotechnologies Corporation Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's Revenue (TTM)?
Adaptive Biotechnologies Corporation Common Stock's Revenue (TTM) is $308.1M, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's Net Income (TTM)?
Adaptive Biotechnologies Corporation Common Stock's Net Income (TTM) is -$63.9M, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's EBITDA?
Adaptive Biotechnologies Corporation Common Stock's EBITDA is -$21.5M, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's Diluted EPS (TTM)?
Adaptive Biotechnologies Corporation Common Stock's Diluted EPS (TTM) is -0.40, based on as-reported figures from SEC (XBRL) filings.
What is Adaptive Biotechnologies Corporation Common Stock's EBITDA Margin?
Adaptive Biotechnologies Corporation Common Stock's EBITDA Margin is -7.0%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+21.5%+35.1%+51.0%+102.4%
Operating expenses
Cost of revenue
Research and development
Sales and marketing
General and administrative
Amortization of intangible assets
Total operating expenses
% of revenue122.0%127.1%117.8%89.1%
Loss from operations
% of revenue-22.0%-27.1%-17.8%10.9%
Interest and other income, net
Interest expense
Loss on revenue interest liability extinguishment———
Net loss
% of revenue-55.8%-28.2%-18.9%10.2%
Add: Net loss (income) attributable to noncontrolling interest
Net loss attributable to Adaptive Biotechnologies Corporation
% of revenue-55.6%-28.3%-18.9%10.2%
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted